Approved revisions

View list of: Pages whose approved revision is not their latest | Unapproved pages | All pages with an approved revision | Pages with invalid approvals

Showing below up to 50 results in range #251 to #300.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. 19. Allergic rhinitis (revision 3104, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  2. 19. Chronic cor pulmonale (revision 4407, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  3. 19. Congenital torticollis (wry neck) (revision 5273, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  4. 19. DNA replication (revision 1394, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  5. 19. Definition, types and organ examples of hyperplasia (revision 1217, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  6. 19. Epidemiological studies: parameters, design (revision 1083, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  7. 19. Epidemiology and prevention of diabetes (revision 1164, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  8. 19. Glomerulonephritis. Classification according to clinical symptoms. Histologic alterations in glomerulonephritides. (revision 97, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  9. 19. Hepatic coma (revision 1866, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  10. 19. Hodgkin lymphoma (revision 4710, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  11. 19. Imaging of the arterial system and arterial diseases. Methods of angiography. Indications and complications. (revision 3387, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  12. 19. Laboratory diagnostic approaches in anaemias. (revision 4105, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  13. 19. Non-melanoma skin cancer (revision 5067, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  14. 19. Pathomechanism and consequences of acute myocardial infarction (revision 1714, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  15. 19. Pharmacology of protein and peptide mediators, the purinergic system and nitric oxide (revision 1998, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  16. 19. Polycystic kidney (infantile sponge kidney) (revision 4635, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  17. 19. Primary and secondary factors of epidemic process (virulence, source of infection, means of transmission, susceptible host) (revision 1121, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  18. 19. Systemic and local immunity (revision 1526, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  19. 19. The placodes, the neural crest and their derivatives. Development of the peripheral nervous system (revision 1661, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  20. 19. Thrombus and postmortem blood clot (revision 4496, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  21. 19. pH regulation (revision 1597, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  22. 19A. Traumatic brain injuries (revision 5776, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  23. 19B. Herpes infection, postherpetic neuralgia (revision 2247, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  24. 1A. The most common types of myopathies and myositis (revision 4931, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  25. 1B. Accidental (provoked) seizures (revision 2210, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  26. 1 – Introduction, gait cycle, symptoms in orthopaedic disorders (revision 5140, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  27. 2. Anaemic infarct of the heart (revision 4387, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  28. 2. Apoptosis in a reactive lymph node (follicular hyperplasia) (revision 4449, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  29. 2. Biochemistry of digestion (revision 1552, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  30. 2. Cardiovascular adaptation in health and disease (revision 1688, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  31. 2. Characterisation of agonist-receptor interaction. Occupancy, affinity, dose-response curve, potency, efficacy (revision 1940, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  32. 2. Definition of health and disease (revision 1064, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  33. 2. Disorders of gastric filling and emptying (revision 1849, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  34. 2. Epidemiology of ischaemic heart disease (revision 1147, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  35. 2. Esophageal carcinoma (revision 4627, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  36. 2. Formation of the trilaminar germ disk and the folding (revision 1641, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  37. 2. Gluconeogenesis (revision 1357, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  38. 2. Helicobacter pylori infection (Warthin-Starry) (revision 4664, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  39. 2. Molecular components of the immune systems (revision 1507, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  40. 2. Otoacoustic emissions, brainstem evoked response audiometry (revision 3054, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  41. 2. Pathology of the salivary glands (revision 37, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  42. 2. Patient preparation before sampling. Proper method to carry out blood (venous, capillary) and urine collection. Type of tubes. (revision 3472, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  43. 2. Postmortal changes. Cell injury and cell death. Causes of cell injury (revision 6026, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  44. 2. Postmortal changes. Cell injury and cell death. Causes of cell injury (revision 6026, approved by Nikolas on 26 November 2024 at 12:26)
  45. 2. Principles of surgical oncology (revision 4989, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  46. 2. Pyodermas (revision 4305, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  47. 2. Role of nutrition in prevention of cancers (revision 1103, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  48. 2. The compound action potential. Conductive properties of various nerve fibers (revision 1203, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  49. 2. The fundamentals of CT and MRI imaging, examination methods. (revision 3201, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  50. 20. CML-CP smear (revision 4712, approved by 127.0.0.1 on 26 November 2024 at 10:56)

View ( | ) (20 | 50 | 100 | 250 | 500)